| Name | Title | Contact Details |
|---|
Reimagining Healthcare. UrgentPoint is committed to combining health and wellness and meeting the patient where they are, every time. With a multispecialty medical group, a medical management company, and an electronic health records technology company...
io is a biotechnology company that focuses on improving the quality of protein and overall nutrition through advanced Ingredient Optimized technology. They improve powders and supplements used in food production, transforming the performance of protein...
Managed Health Care Associates, Inc. (MHA) is not only the country`s largest alternate site GPO, but also has established itself as a leading health care services and technology company. This evolution reflects our commitment to stay abreast of changes in the alternate site health care market and invest in innovative solutions, technologies and services for our members including long-term care pharmacies, infusion pharmacies, specialty pharmacies, home medical equipment providers and assisted living and skilled nursing facilities.
Abbott is a global healthcare company that conducts innovative research and manufactures products for human health through every life stage. They bring new products and technologies to the world in nutrition, diagnostics, medical devices and branded ge...
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.